The NeurologyLive® Insomnia Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the disorder of sleepiness.
June 5th 2024
Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.